三氧化二砷与急性早幼粒细胞白血病综述
A review of arsenic trioxide and acute promyelocytic leukemia.
作者信息
Alimoghaddam Kamran
机构信息
Professor of medicine, research institute for oncology hematology and stem cell transplantation, Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave. Tehran, 14114, IRAN.
出版信息
Int J Hematol Oncol Stem Cell Res. 2014 Jul 1;8(3):44-54.
Arsenic Trioxide is an old drug that has recently re- introduced into new medicine. It is very potent against a specific type of leukemic cells harboring translocation between chromosomes 15 and 17. It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia, including for remission induction of relapsed cases, or as first-line treatment. It is also useful in the consolidation/maintenance phase of treatment. Many trials are ongoing to determine the best and optimum schedule for this drug as a single agent or in combination with other drugs. In the future, its indications might extend to other malignancies. In this review, we will study biologic effects of arsenic trioxide on APL cells and the results of clinical trials on the treatment of APL. We will also discuss the toxicity and minimal residual detection during patient follow-up.
三氧化二砷是一种老药，最近重新应用于新药领域。它对特定类型的白血病细胞具有很强的杀伤力，这些细胞存在15号和17号染色体之间的易位。已经证明，这种药物对急性早幼粒细胞白血病的各个阶段均有效，包括用于复发病例的诱导缓解，或作为一线治疗。它在治疗的巩固/维持阶段也很有用。目前正在进行许多试验，以确定这种药物作为单一药物或与其他药物联合使用的最佳和最优方案。未来，其适应症可能会扩展到其他恶性肿瘤。在本综述中，我们将研究三氧化二砷对急性早幼粒细胞白血病细胞的生物学效应以及治疗急性早幼粒细胞白血病的临床试验结果。我们还将讨论患者随访期间的毒性和微小残留检测。
Zotero 插件